THE IMPORTANCE OF A PLATELET-ACTIVATING FACTOR (PAF) ANTAGONIST IN ALLERGY TREATMENT.

Bringing relief to Allergic Rhinitis and Urticaria sufferers.

Platelet-activating factor (PAF) is today considered an important mediator in allergic and inflammatory reactions1. While histamine is the primary mediator involved in the pathophysiology of Allergic Rhinitis and chronic Urticaria, it is clearly not the only mediator involved in the inflammatory process2. Histamine and platelet-activating factor (PAF) both play an important role in Allergic Rhinitis3.

In an allergic reaction, during the release of mediators, one of the key molecules is PAF. There are PAF receptors both from the mast cell itself as well as over the inflammatory pathway. PAF generates a lot of inflammation4.

There is an emerging view that drugs which can inhibit a broader range of inflammatory processes may prove to be more effective in providing symptomatic relief in both Allergic Rhinitis and chronic Urticaria2.

Antihistamines which can inhibit a broader range of inflammatory agents such as histamine and PAF are more effective in providing symptomatic relief in allergy patients5.

Rupanase, from iNova Pharmaceuticals, is the first antihistamine to have an effect on both histamine and PAF6. It is a powerful, non-sedating antihistamine and a potent inhibitor of PAF6.

The dual action of Rupanase 10mg targets the allergic cascade at multiple points to block mediators, Histamine and PAF, in both the allergic and inflammatory responses associated with Allergic Rhinitis and Urticaria7.

The active ingredient, Rupatadine, has an anti-allergic and anti-inflammatory profile6. Rupanase (Rupatadine) provides chronic Urticaria symptom relief within 12 hours8, providing up to 24-hour relief with a convenient once-a day-dosage and is well tolerated9.

Furthermore, Rupatadine acts within 30 minutes to relieve the symptoms of Allergic Rhinitis and relieves nasal congestion within two hours7.

Worldwide, Allergic Rhinitis affects between 10 % and 30 % of the adult population10 and is a common paediatric condition11. In a worldwide study of over one million adolescents aged 13 and 14 years, the prevalence was 14.6%11.

The impact of Allergic Rhinitis on a patient cannot be underestimated. In fact, 66 % of patients report that nasal allergies impact daily life, 52% of patients report that nasal allergies symptoms affect work performance and 40% of patients report moderate to severe impact on sleep5.

Patients using Rupanase have reported significant improvements in the control of nasal symptoms, severity of disease and health-related Quality of Life12.

Urticaria can be a debilitating condition. Patients have reported impaired Quality of Life (QoL) due to sleep disruption, energy loss, fatigue, social isolation and emotional/sexual disturbances13.

Rupanase has been shown to provide effective and lasting relief from pruritus and wheals; after the first dose observed at 24 hours and relief lasting up to week four of the clinical study13.

Help your allergy patients find symptom relief of Allergic Rhinitis and Urticaria with Rupanase7.

For more information, go to www.inovapharma.co.za.

 

References
  1. National Centre for Biotechnology Information (NCBI) –  Platelet-activating factor (PAF) in allergic diseases: inhibitory effects of anti-allergic drugs, ketotifen and three kampo medicines on PAF production. https://www.ncbi.nlm.nih.gov/pubmed/1726443 (Website accessed on 24 April 2018).
  2. Mullol J et al. Rupatadine in allergic rhinitis and chronic urticaria Allergy. 2008 Apr;63 Suppl 87:5-28. doi: 10.1111/j.1398-9995.2008.01640 (https://www.ncbi.nlm.nih.gov/pubmed/18339040). Website accessed on 9 May 2018
  3. Alfaro, V. Role of histamine and platelet-activating factor in allergic rhinitis. Journal of physiology and biochemistry 60(2):101-11 · July 2004 (https://www.researchgate.net/publication/8257462_Role_of_histamine_and_platelet-activating_factor_in_allergic_rhinitis) Website accessed on 9 May 2018
  4. Hit it Hard – Medical Chronicle 01 April 2015 (http://academic.sun.ac.za/Health/Media_Review/2015/13Apr15/files/Dr%20_Willie_Visser.pdf) Website accessed on 9 May 2018
  5. Church MK. et al. The Scope of Pharmacological and Clinical Effects of Modern Antihistamines with a Special Focus on Rupatadine. WAO Journal. 2010; S1-S16
  6. Picado C. Rupatadine: pharmacological profile and its use in the treatment of allergic disorders. Expert Opinion in Pharmacotherapy 2006;7(14):1989-2001.
  7. Mullol J et Al. Update on Rupatadine in the Management of Allergic Disorders European Journal of Allergy and Immunology. Volume 70 • Supplement 100 • January 2015
  8. Gimenez-Arnau A, et al. Rupatadine fast onset of action. Pruritus and number of wheals relieve in patients suffering from chronic urticaria, a pooled analysis. Poster presented at the European Academy of Dermatology and Venereology Congress (EADV), May 2007.
  9. RUPANASE package insert.
  10. Pawankar R et al. (eds) WAO White Book on Allergy 2011 World Allergy Organization
  11. Barr, JG. Allergic rhinitis in children. BMJ 2014 (https://www.bmj.com/content/349/bmj.g4153) Website accessed on 9 May 2018
  12. Maiti R et al. Rupatadine and levocetirizine for seasonal Allergic Rhinitis. Arch Ottlaryngol Head Neck Surg 2010; 136(8):796-800.
  13. Gimenez-Arnau A. et al. Rupatadine in the treatment of chronic idiopathic Urticaria: a double-blind, randomized, placebo-controlled multicentre study. Allergy 2007; 62: 539-546